University of Arizona Mel & Enid Zuckerman College of Public Health
Roy P. Drachman Hall, Room B109
1295 N. Martin Ave.
Tucson, AZ 85721
University of Arizona College of Pharmacy and UA Cancer Center Present
TOPIC: “Macrocyclic Peptide Antagonists of MDM2 and MDMX: Drug Design, Cell Permeability and Translational Medicine”
SPEAKER: Tomi K. Sawyer, PhD, Distinguished Scientist, Discovery Chemistry Modalities, Merck & Company Inc.
When: Friday, August 3, 2018
Presentation: Noon–1 p.m.
Where: Roy P. Drachman Hall, Rm. B109, 1295 N. Martin Ave., Tucson, AZ 85721
There is a renaissance in peptide drug discovery with respect to tackling intracellular targets, including protein–protein interactions and protein–DNA/RNA interactions. With respect to such targets for the advancement of novel cancer therapies, pioneering basic research provided the framework to identify the first dual antagonists of MDM2 and MDMX. Further iterative optimization led to ATSP-7041, a macrocyclic a-helical peptide, as a progenitor of a drug development candidate (now in Phase 1/2 clinical trials). This presentation will highlight ATSP-7041 as a benchmark molecule for new drug design concepts, cell permeability screening tools, and translational medicine of an emerging super-class of macrocyclic peptide modality.
- To share a vision of peptide drug discovery to explore intracellular target space.
- To exemplify new drug design concepts and cell permeability screening tools enabling peptide research and development.
Host: Rick G. Schnellmann, PhD, Dean, University of Arizona College of Pharmacy
Lunch will be available. Please RSVP to email@example.com